RxNorm 1657750

pembrolizumab 100 MG in 4 ML Injection

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 1657750 unique identifier include: pembrolizumab 100 MG in 4 ML Injection (7251679), pembrolizumab 100 MG per 4 ML Injection (7251678) and 4 ML pembrolizumab 25 MG/ML Injection (7251671).

RxNorm Atom ID: 7251679 - Prescribable Name
pembrolizumab 100 MG in 4 ML Injection

RXCUI:
1657750 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251679 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
pembrolizumab 100 MG in 4 ML Injection - Description of concept identifier
Term Type (TTY):
PSN - Term type in source with name and description
Term Type Name:
Prescribable Name - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
Code:
1657750 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 7251678 - Synonym
pembrolizumab 100 MG per 4 ML Injection

RXCUI:
1657750 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251678 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
pembrolizumab 100 MG per 4 ML Injection - Description of concept identifier
Term Type (TTY):
SY - Term type in source with name and description
Term Type Name:
Synonym - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity. - Description of term type in source
Code:
1657750 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 7251671 - Semantic Clinical Drug
4 ML pembrolizumab 25 MG/ML Injection

RXCUI:
1657750 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
7251671 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
4 ML pembrolizumab 25 MG/ML Injection - Description of concept identifier
Term Type (TTY):
SCD - Term type in source with name and description
Term Type Name:
Semantic Clinical Drug - Name of term type in source
Term Type Description:
Ingredient + Strength + Dose Form - Description of term type in source
Code:
1657750 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 7251671 Attributes

PropertyValueExplanation
RXN AI{1547546} 1547545RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM{1547546} 1547545RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH25 MG/MLAvailable drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM{1547546} AISource of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUGUSDrug available for use in Humans
RXN QUANTITY4 MLNormal Form quantity factor

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Pembrolizumab Injection


Pembrolizumab injection is used: to treat melanoma (a type of skin cancer) that cannot be treated with surgery or has spread to other parts of the body, or in combination with other chemotherapy medications to treat and prevent the return of melanoma after surgery to remove it and any affected lymph nodes; to treat certain types of non-small-cell lung cancer (NSCLC) that cannot be treated with surgery, other chemotherapy medications, or radiation therapy or that has spread to other parts of the body or worsened during or after it was treated with platinum containing chemotherapy medications (cisplatin, carboplatin), or in combination with other chemotherapy medications (paclitaxel, pemetrexed) to treat certain types of NSCLC that has spread to other parts of the body; to treat a certain type of head and neck cancer that keeps coming back or has spread to other parts of the body and cannot be removed by surgery. It can also be used in combination with fluorouracil and a platinum containing chemotherapy medications (cisplatin, carboplatin) to treat a certain type of head and neck cancer that keeps coming back or has spread to other parts of the body and cannot be treated with surgery. Pembrolizumab is also used to treat a certain type of head and neck cancer that has worsened or spread to other parts of the body during or after treatment with chemotherapy medications; to treat a certain type of Hodgkin's lymphoma (Hodgkin's disease) in children and adults that did not get better with other chemotherapy treatments or got better but returned after treatment with other chemotherapy medications and in children after being treated two or more times with other chemotherapy medications; to treat a certain type of primary mediastinal B-cell lymphoma (PMBCL; non-Hodgkin lymphoma) in children and adults that did not get better with other chemotherapy treatments or returned after being treated two or more times with other chemotherapy medications; to treat a certain type of urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) that has spread to nearby tissues or other parts of the body in people who cannot receive platinum containing chemotherapy medications (cisplatin, carboplatin), or whose cancer worsened during or after it was treated with these chemotherapy medications; to treat a certain type of bladder cancer in people who did not get better with another medication (Bacillus Calmette-Guerin; BCG therapy) and who are unable to or who have decided not to be treated by surgery to remove the bladder; to treat certain types of colorectal cancer (cancer that begins in the large intestine) and certain types of solid tumors as a first treatment in children and adults that cannot be treated by surgery or that has spread to other parts of the body or in those that worsened after it was treated with other chemotherapy medications; to treat certain types of gastric cancer (cancer of the stomach) or cancer located in the area where the stomach meets the esophagus (the tube between the throat and stomach) that has returned or that has spread to other parts of the body during or after 2 or more chemotherapy treatments; to treat a certain type of esophageal cancer that has returned and has spread to nearby tissues or other parts of the body after treatment with one or more other chemotherapy medications and cannot be treated with surgery or radiation therapy; to treat certain types of cervical cancer (cancer that begins in the opening of the uterus [womb]) that has returned or has spread to other parts of the body during or after treatment with another chemotherapy medication; to treat certain types of hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated unsuccessfully with sorafenib (Nexafar); to treat Merkel cell carcinoma (MCC; a type of skin cancer) in children and adults that has returned and spread to nearby tissues or other parts of the body; in combination with axitinib (Inlyta) to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys); in combination with lenvatinib (Lenvima) to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy; to treat certain types of solid tumors that has spread to other parts of the body or cannot be treated by surgery in adults and children who were previously treated unsuccessfully with another chemotherapy medication and do not have other satisfactory treatment options; to treat certain types of cutaneous squamous cell carcinoma (CSCC; skin cancer) that has returned or has spread to other parts of the body and cannot be treated with surgery or radiation therapy; and in combination with chemotherapy to treat a certain type of breast cancer that has returned to nearby tissues or has spread to other parts of the body and cannot be treated with surgery.Pembrolizumab injection is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.